Total Funding
47
Total FundingSeries B raised
Growth Score
pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
42657
VelosBio is a next-generation oncology company, developing novel antibody-drug conjugates to treat haematological cancers.
- Dave Johnson: CEO & Founder
About the Company
VelosBio is an operator of a clinical-stage biopharmaceutical company intended to develop novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. The company's ROR1-directed therapeutics is a cell-surface protein that is expressed on many hematologic and solid tumors but is absent from normal tissues,
making it an attractive tumor-specific therapeutic target and has demonstrated positive preclinical results in tumor models, enabling institutions to get novel targeted therapies for use as monotherapy or in combination across a broad range of cancers.
It was founded in 2017 and headquartered in San Diego, California.
